The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting-Reference-Cited by-同舟云学术

The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting

Published:2021-11-18 Issue:12 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Wikell A.¹²,Jonsson J.³,Dyrdak R.⁴⁵,Henningsson A. J.⁶⁷⁸,Eringfält A.⁹,Kjerstadius T.¹⁰,Hålldin E.¹¹,Baqir H.¹²,Kholod V.¹²,Sturegård E.¹³,Bruchfeld J.¹²,Schön T.⁶¹⁴¹⁵^ORCID

Affiliation:

1. Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden

2. Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

3. The Public Health Agency of Sweden, Solna, Sweden

4. Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden

5. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

6. Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

7. Department of Clinical Microbiology in Jönköping, Region Jönköping County, Linköping University, Linköping, Sweden

8. Department of Clinical Microbiology in Linköping, Linköping University, Linköping, Sweden

9. Department of Clinical Microbiology, Halland County Hospital, Halmstad, Sweden

10. Laboratory Medicine, Clinical Microbiology, Central Hospital, Karlstad, Sweden

11. Department of Clinical Microbiology, Västerås County Hospital, Västerås, Sweden

12. Department of Clinical Microbiology, Linköping University Hospital, Linköping, Sweden

13. Clinical Infection Medicine, Department of Translational Medicine, Lund University, Lund, Sweden

14. Department of Infectious Diseases, Kalmar County Hospital, Linköping University, Kalmar, Sweden

15. Department of Infectious Diseases, Linköping University, Linköping, Sweden

Abstract

Quantiferon-TB Gold Plus (QFT-Plus) is an interferon gamma release assay used to diagnose latent tuberculosis (LTB). A borderline range (0.20 to 0.99 IU/ml) around the cutoff (0.35 IU/ml) has been suggested for the earlier QFT version.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01370-21

Reference27 articles.

1. The global prevalence of latent tuberculosis: a systematic review and meta-analysis

2. World Health Organization. 2015. The End TB Strategy. World Health Organization, Geneva, Switzerland.

3. Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy

4. Qiagen. 2016. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA package insert—the whole blood IFN-γ test measuring responses to ESAT-6 and CFP-10 peptide antigens. 1083163 Rev. 04. Qiagen, Valencia, CA.

5. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of concordance of new QuantiFERON-TB Gold Plus platforms for Mycobacterium tuberculosis infection diagnosis in a prospective cohort of household contacts;Microbiology Spectrum;2024-08-06

2. Prevalence and Predictors of Tuberculosis Infection in Children and Adolescents in Rural Uganda: A Cross-sectional Study;Pediatric Infectious Disease Journal;2024-07-15

3. The Cascade of Care in Management of Solid Organ Transplant Candidates With Latent Tuberculosis Infection;Transplantation Direct;2024-06-20

4. A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection;Clinical Chemistry;2024-02-01

5. Accuracy of QuantiFERON in active tuberculosis suspects with comorbidities and nontuberculous mycobacterial infection in Northern California;Journal of Clinical Microbiology;2023-11-21